Targeted exon skipping of a *CEP290* mutation rescues Joubert syndrome phenotypes in vitro and in a murine model

Simon A. Ramsbottom1,2, Elisa Molinari1,2, Shalabh Srivastava2,3,4, Flora Silberman5, Charline Henry5, Sumaya Alkanderi6, Laura A. Devlin7, Kathryn White7, David H. Steel8,9, Sophie Saunier2, Colin G. Miles8,9, and John A. Sayer2,3,4

*Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom; 2Renal Services, The Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, United Kingdom; 3Laboratory of Hereditary Kidney Diseases, INSERM UMR 1163, Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; 4Electron Microscopy Research Services, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom; 5Sunderland Eye Infirmary, Sunderland SR2 9HP, United Kingdom; and 6National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne NE4 5PL, United Kingdom

Edited by Martin R. Pollak, Harvard Medical School, Beth Israel Deaconess Medical Center, Brookline, MA, and approved October 19, 2018 (received for review June 1, 2018)

Genetic treatments of renal ciliopathies leading to cystic kidney disease would provide a real advance in current therapies. Mutations in *CEP290* underlie a ciliopathy called Joubert syndrome (JBTS). Human disease phenotypes include cerebral, retinal, and renal disease, which typically progresses to end-stage renal failure (ESRF) within the first two decades of life. While currently incurable, there is often a period of years between diagnosis and ESRF that provides a potential window for therapeutic intervention. By studying patient biopsies, patient-derived kidney cells, and a mouse model, we identify abnormal elongation of primary cilium as a key pathophysiological feature of *CEP290*-associated JBTS and show that antisense oligonucleotide (ASO)-induced splicing of the mutated exon (41, G1890±) restores protein expression in patient cells. We demonstrate that ASO-induced splicing leading to exon skipping is tolerated, resulting in correct localization of *CEP290* protein to the ciliary transition zone, and restoration of normal cilium length in patient kidney cells. Using a gene trap *Cep290* mouse model of JBTS, we show that systemic ASO treatment can reduce the cystic burden of diseased kidneys in vivo. These findings indicate that ASO treatment may represent a promising therapeutic approach for kidney disease in *CEP290*-associated ciliopathies.

Significance

The treatment of genetic kidney disease is challenging, as this requires both the correction of the underlying gene defect and the delivery of the treatment. Here we show that by using antisense oligonucleotides, we can induce exon skipping of a mutated exon in *CEP290*, within renal epithelial cells derived from a patient with a ciliopathy syndrome called Joubert syndrome. This treatment rescues the truncated *CEP290* protein to a near full-length protein and restores the ciliary phenotype. In a *Cep290* murine model of Joubert syndrome, exon skipping is achievable with systemic treatment of an antisense oligonucleotide, which rescues both the cilary and kidney disease phenotypes. This work paves the way toward personalized genetic therapies in patients with inherited kidney diseases.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1S.A.R., E.M., and S. Srivastava contributed equally to this work.

2To whom correspondence may be addressed. Email: colin.miles@newcastle.ac.uk or john.sayer@newcastle.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1809432115/-/DCSupplemental.

Published online November 16, 2018.

www.pnas.org/cgi/doi/10.1073/pnas.1809432115

Joubert syndrome | *Cep290* | cystic kidney | antisense oligonucleotide therapy | ciliopathy
could be modeled to predict genetic pleiotropy associated with CEP290 mutations (13). Indeed, confirming this hypothesis, endogenous basal exon skipping and nonsense-associated altered splicing has been documented in patient fibroblasts with nonsense mutations in CEP290 with mild retinal phenotypes (14). These observations are reminiscent of the Duchenne/Becker muscular dystrophy paradigm (15), which responds to targeted exon skipping therapies (16, 17). Given that most of the CEP290 protein consists of repeated coiled-coil domains, often encoded by a single exon, CEP290 seems an ideal candidate for ASO-mediated exon skipping therapy.

Results
Clinical and Genetic Investigations. Here we describe a 14 y old boy (JBTS-AA) from consanguineous parents (Fig. 1A) affected with JBTS. He initially presented with congenital ptosis and visual...
failure secondary to an early onset retinal degeneration (SI Appendix, Fig. S1) and subsequently developed ataxia and significant renal impairment (Table 1). Clinical investigations revealed hyperchogenic kidneys showing cystic change and loss of corticomедullary differentiation (Fig. 1B), consistent with a diagnosis of nephronophthisis, and a ‘molar tooth’ sign on brain MRI (Fig. 1C) which is due to cerebellar vermis aplasia and is the defining feature of JBTS. Molecular genetic investigations in JBTS-AA confirmed a homozygous nucleotide substitution leading to a stop codon (c.5668G>T; p.G1890*) in exon 41 of CEP290 (Fig. 1D). This mutation is predicted to lead to a truncated CEP290 protein lacking numerous C-terminal coiled-coil domains (Fig. 1E).

Phenotyping Using Primary Renal Epithelial Cells. To characterize the cellular and molecular consequences of this mutation, we derived primary, nontransformed human urine-derived renal epithelial cells (hURECs) from patient JBTS-AA and age/sex matched controls (WT). Western blotting, using a CEP290 C-terminal antibody, confirmed an almost complete absence of full-length CEP290 protein (Fig. 1F) from patient hURECs. Immunofluorescence analysis of cilia structure revealed elongated primary cilia on patient hURECs (JBTS-AA) compared with control (WT) cells (Fig. 1G–I). This was confirmed by scanning electron microscopy (Fig. 1J–L). In terms of percentage ciliation rates in hURECs, there was no difference between wild-type and JBTS-AA cells (SI Appendix, Fig. S2). We have previously described an elongated cilia phenotype in hURECs derived from an unrelated JBTS patient harboring CEP290 mutations (9), suggesting abnormally long primary cilia may be a common, renal feature of JBTS.

To investigate this further, we carried out immunofluorescence analysis of cilia structure in two further (unrelated) JBTS patients with CEP290 mutations and kidney failure (SI Appendix, Table S1). Immunofluorescence staining of renal biopsies for acetylated tubulin and ARL13B revealed the presence of elongated and tortuous primary cilia in both patients compared with normal kidney (SI Appendix, Fig. S3) confirming that the elongated primary cilia found on patient hURECs accurately reflect the phenotype observed in vivo. It is intriguing to note that elongated cilia have also been found in a wide range of other ciliopathy models including: Bbs-4 null mice (18), jck mice (19), Meckel syndrome (20), Kif7 mutated cells (21), and JBTS secondary to KIAA0556 mutations (22), suggesting elongated primary cilia may be a widespread feature of ciliopathies in general and that correction of this phenotype attenuates cystic kidney disease (23).

Targeted Exon Skipping of CEP290 Rescues Phenotype in Primary Renal Epithelial Cells. Exon 41 of CEP290 is 123 nucleotides in length and encodes a single, discrete, coiled-coil domain of the protein (SI Appendix, Fig. S4). Consequently, a splice-blocking ASO targeted to the splice donor site of exon 41 would be predicted to induce skipping of exon 41, while maintaining the correct reading frame, to produce a transcript encoding a near full-length protein of 2,438 amino acids (286 KDa) that contains a normal C terminus and is lacking only a single coiled-coil domain (SI Appendix, Fig. S4). To test the functionality of the splice blocking ASO, we carried out RT-PCR analysis of the CEP290 transcript from hURECs and confirmed efficient ASO-induced alternative splicing, skipping exon 41 (Fig. 2A). In the absence of any available N-terminal CEP290 antibodies, quantitative RT-PCR of the CEP290 transcript targeted to exons 6–7, upstream of the mutation in JBTS-AA, showed that CEP290 expression levels in JBTS-AA hURECs are reduced to ∼20% of wild-type levels, suggesting degradation of the mutant mRNA transcript; levels of the transcript are rescued following ASO-induced splicing (SI Appendix, Fig. S5A). Furthermore, we observed restoration of protein expression by Western blot in ASO-treated JBTS-AA hURECs, with near wild-type levels of protein detectable with the C-terminal CEP290 antibody at 24 h post treatment, which persisted for 96 h (Fig. 2B). In addition to the structural ciliary changes observed, JBTS-AA hURECs showed an increase in SIHH levels (∼fourfold) indicating dysregulation of ciliary signaling. Transcript levels of SIHH were, however, not fully rescued by ASO treatment (SI Appendix, Fig. S5B).

Despite lacking a single coiled-coil domain encoded by exon 41, the near full-length CEP290 protein correctly localized to the transition zone in ASO-treated JBTS-AA hURECs (SI Appendix, Fig. S6); this provides evidence that the removal of exon 41 in CEP290 does not affect protein localization. Given the correct localization of the restored protein, lacking a single coiled-coil domain, we investigated whether this could ameliorate the phenotype of JBTS-AA hURECs. Primary cilia were analyzed using fluorescence microscopy directed at ARL13B and a significant reduction in the length of JBTS-AA primary cilia, equivalent to wild-type cilia was observed after 48 h (Fig. 2 C and D); this was also confirmed by scanning electron microscopy (Fig. 2 E and F). It is noteworthy that the reduction in cilia length is dramatic and significant even at 24 h, indicating a rapid response to ASO treatment. This extends our previous findings, that pharmacological treatments can reduce cilia length in JBTS hURECs (9), and provides evidence to suggest that this phenotype, which relies upon the continued presence of the mutation, is reversible. Importantly, ASO treatment of wild-type control hURECs had no effect on the length of the primary cilia, suggesting that the absence of the coiled-coil domain encoded by exon 41 can be tolerated.

Targeted Exon Skipping of Cep290 in Vivo Rescues Ciliary and Cystic Kidney Disease Phenotypes. Having shown a positive effect of ASO treatment on primary, nontransformed patient kidney cells ex vivo,

### Table 1. Molecular and clinical characteristics of affected patient (JBTS-AA)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>JBTS-AA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity and consanguinity</td>
<td>Pakistani, parents first cousins, segregation confirmed</td>
</tr>
<tr>
<td>Renal ultrasound scan findings</td>
<td>Increased echogenicity, corticomedullary cysts, loss of corticomedullary differentiation</td>
</tr>
<tr>
<td>Kidney function</td>
<td>Chronic kidney disease stage 3, creatinine 1.91 mg/dL (aged 14 y)</td>
</tr>
<tr>
<td>Ocular symptoms (age of onset, y)</td>
<td>Congenital ptosis (1 mo) Early onset retinal degeneration initially diagnosed with visual failure (2 mo)</td>
</tr>
<tr>
<td>Central nervous symptoms</td>
<td>Ataxia, cerebellar vermis aplasia/hypoplasia with “molar tooth sign” on brain MRI</td>
</tr>
<tr>
<td>Nucleotide alterations</td>
<td>Homozygous c.5668G&gt;T (exon 41)</td>
</tr>
<tr>
<td>Alteration in coding sequence</td>
<td>Homozygous Gly1890*</td>
</tr>
<tr>
<td>Reference sequence</td>
<td>NM_025114</td>
</tr>
<tr>
<td>SNP ID</td>
<td>rs137852832</td>
</tr>
<tr>
<td>ExAC allele frequency</td>
<td>0.0001452</td>
</tr>
</tbody>
</table>

*Stop codon

Ramsbottom et al. | PNAS | December 4, 2018 | vol. 115 | no. 49 | 12491

* Downloaded by guest on August 14, 2021

**MEDICAL SCIENCES**
we wished to determine whether a similar strategy could be applied in vivo. The most faithful model of JBTS described to date is the Cep290Gt(CCGTGCCG)Wtsi mouse line (which we will refer to as Cep290Gt) previously reported as Cep290P,acC that presents with a renal-retinal-brain phenotype caused by insertion of a “gene trap” within Cep290 after exon 25 (8). As the Cep290Gt mice were produced from embryonic stem (ES) cells containing an intronic splice acceptor/β-galactosidase/neomycin phosphotransferase (SA-IREs-βGEO) “gene trap” cassette (3,975 bp), we designed a new oligonucleotide to block the splice acceptor of the gene trap cassette (vivo-ASOG) to restore full-length Cep290 transcript and protein (SI Appendix, Fig. S7). As proof of concept, treatment of immortalized kidney cells derived from homozygous Cep290P,acC mice with vivo-ASOG resulted in a modest restoration of correct splicing between exons 25 and 26, with a concomitant decrease in exon 25 splicing into SA-IREs-βGEO, and a return of a full-length Cep290 protein detected by Western blotting using a C-terminal Cep290 antibody (SI Appendix, Fig. S7). In contrast to ASO treatment of JBTS-AA hURECs, wild-type levels of transcript/protein were not achieved in the transformed mouse cell line following vivo-ASOG treatment. RT-PCR analysis with a panel of primers located across the SA-IREs-βGEO cassette suggests that we do not see complete restoration of wild-type transcript levels (SI Appendix, Fig. S7), possibly due to the presence of cryptic splice sites within the SA-IREs-βGEO cassette (24, 25). However, given that Cep290 is not haploinsufficient and it has been reported that small fragments of CEP290 can ameliorate LCA (26), we reasoned that even subwild-type levels of protein may be beneficial. Therefore, we proceeded to investigate the potential effects of a modest restoration of full-length protein in vivo, in Cep290Gt mice. Systemic administration of vivo-ASOG was carried out via a series of i.v. injections over 10 d. RT-PCR analysis and sequencing of whole kidney RNA revealed correctly spliced transcripts (Fig. 34 and SI Appendix, Fig. S8), consistent with splicing from exon 25 to exon 26, skipping SA-IREs-βGEO. Full-length Cep290 protein was detected by a Western blot of whole kidney extracts using C-terminal Cep290 antibody (Fig. 3B) indicating that vivo-ASOG was capable

**Fig. 2.** ASO-induced exon skipping restores CEP290 protein expression and rescues cilia defects in patient hURECs. (A) Gene expression analysis using RT-PCR of hURECs obtained from patient JBTS-AA. Lane 1 demonstrates CEP290 (predicted 520 bp) expression in untreated cells. Lane 2 shows RT-PCR products obtained after treatment with 1 μM ASO directed toward exon 41 splice-junction. ASO-mediated exon skipping leads to a shorter CEP290 mRNA transcript (predicted product size of 397 bp). (B) CEP290 exon 41 skipping induced by ASO of JBTS-AA hURECs demonstrates the rescue of CEP290 protein translation. WT hURECs protein lysates demonstrate the presence of full-length CEP290 protein (290 kDa), which was not adversely affected by ASO treatment. JBTS-AA hURECs protein lysates show a near absence of full-length protein. JBTS-AA ASO-treated hURECs show rescue of near full-length CEP290 protein translation at 24 h post treatment, which persists for 96 h. BETA-ACTIN (42 kDa) serves as loading control. (C) Immunofluorescence (IF) microscopy of wild-type hURECs, untreated JBTS-AA hURECs, and JBTS-AA hURECs treated with ASO to induce exon skipping of exon 41 rescues the phenotype of long cilia. DAPI- blue (Nuclei), Green - ARL13B (Ciliary membrane). (Scale bar: 5 μm.) (D) IF quantification of the cilia length in JBTS-AA hURECs followed by treatment with ASO. Cilia length was quantified after treatment with 1 μM ASO at 24 h and 48 h. The mean cilia length measured for untreated JBTS-AA cilia (n = 24) was 8.36 μm (detected using ARL13B antibodies). The mean cilia length after treatment with 1 μM ASO for 24 h (n = 50) was 4.56 μm and after treatment for 48 h (n = 50) was 4.02 μm. The mean cilia length of WT hURECs cilia (n = 49) before treatment was 3.96 μm and after treatment with 1 μM ASO for 48 h (n = 50) was 3.87 μm. Data are shown as scattergrams with mean shown. *P < 0.0001 determined by one-way ANOVA. (E) Scanning electron microscopy of hURECs in WT, untreated JBTS-AA, and JBTS-AA treated with ASO and imaged at 48 h. (Scale bar: 2 μm.) (F) Electron microscopy (EM) quantification of the cilia length in WT, JBTS-AA, and JBTS-AA+ ASO treated hURECs rescued by treatment with ASO. The mean cilia lengths were: WT hURECs 4.8 μm, JBTS-AA 6.74 μm, and JBTS-AA + ASO 3.78 μm. Data are shown as scattergrams with mean indicated. *P < 0.05 and **P < 0.01, one-way ANOVA. n = 10 cilia for each group. n.s., not significant.
inducing skipping of SA-IRES-βGEO in kidney, in vivo. Whole murine kidney tissue protein extract was used to assess the response of ciliary signaling molecules. Compared with wild-type controls, Cep290<sup>Gt/Gt</sup> kidneys had increased Shh signaling, as demonstrated by a rise in the Gli3 activator to repressor ratio that was partially restored by treatment with vivo-ASOG<sup>Gt</sup> (SI Appendix, Fig. S5 C and D). Immunofluorescence analysis revealed an increase in the length of primary cilia (Arl13b staining) in cortical collecting ducts (aquaporin-2 staining) in homozygous Cep290<sup>Gt/Gt</sup> mice compared with wild-type littermates (Fig. 3 C and D), highlighting a further similarity between the Cep290<sup>Gt/Gt</sup> mouse model and JBTS patients with CEP290 mutations (SI Appendix, Fig. S2). This increase in cilia length of cortical collecting duct cells could be rescued by ∼50% by systemic vivo-ASO<sup>Gt</sup> treatment, similar to the 24 h ASO treatment of JBTS-αA hURECs. Having shown full-length protein and a shortening of the abnormally long primary cilium following vivo-ASO<sup>Gt</sup> treatment, we carried out quantitative assessment of cystic burden in vivo-ASO<sup>Gt</sup> treated and untreated Cep290<sup>Gt/Gt</sup> kidneys. Remarkably, vivo-ASO<sup>Gt</sup> treatment resulted in a striking and significant improvement in cystic index (Fig. 3 E and F) of 37%, indicating that measurable therapeutic benefit can be achieved in vivo by relatively modest levels of ASO-induced splice blocking.

**Discussion**

We have shown that in human renal epithelial cells from a patient with JBTS secondary to a nonsense mutation in exon 41 of CEP290, ASO-mediated exon skipping can ameliorate the ciliary phenotype and restore localization of a near full-length CEP290 protein to the base of the cilium. We have then validated this approach in vivo, by using a different ASO targeting strategy to promote alternate splicing of a murine gene trap insertion within intron 25 of Cep290, thereby rescuing, in part, full-length Cep290 transcript and protein to achieve a phenotypic rescue of renal ciliary length in vivo as well as the cystic kidney disease. The observed phenotypic changes in murine and human cells, as well as in mouse kidney tissue following treatment with two completely different ASOs indicate that the observed effects are specific, and result from the restoration of CEP290/Cep290.

Overall, these data have several important implications. Firstly, systemic delivery of ASOs can ameliorate kidney pathology in a whole animal model. In addition, ASOs can rescue disease phenotypes after disease has become established in both JBTS patient-derived cells and an animal model, confirming the indications from pharmacological treatments that the cystic kidney disease is reversible. Finally, ASO-mediated exon skipping is tolerated at the level of protein localization, as the removal of a coiled-coil...
domain does not result in the mislocalization of the CEP290 protein. Given that many CEP290 mutations cluster in the C-terminal coiled-coil-rich region and are potentially skippable (SI Appendix, Fig. S9), it is tempting to speculate that these mutations may also be amenable to ASO-mediated therapy.

One limitation of this study is that despite G1890* being one of the most common mutations, we have not extended our human studies to other skippable exons in CEP290. Here true personalized medicine approaches, using patient-derived cells, such as we have used with patient JBTAs-AA, will be required to determine if exon skipping of alternate exons, which may contain more crucial functional domains than exon 41, are possible. The direct consequences of skipping exons within the CEP290 gene require testing in both ex vivo and in vivo systems. A Cep290 mouse model, mimicking the human G1890* mutation, would be required to determine fully the effects of ASO-mediated exon skipping in both kidney and extrarenal tissues. Given the ease of access for subretinal injections, to date there has been a focus on ASO-based therapies for human retinal disease, including CEP290-associated LCA (10, 27). As our work has shown, systemic delivery of ASOs is possible and seems to ameliorate kidney disease; this needs to be assessed more fully in renal tissues as well as retinal tissues for dosing regimens and timing of therapies. However, given the efficiency of ASO-mediated exon skipping observed in patient kidney cells, where the next available splice acceptor is used almost exclusively, this is likely to confirm that ASO treatments should be considered as a promising therapeutic approach. It seems likely, following on from the success of ASO-based therapy for targeting CEP290 retinal disease, that ASO-based therapy for CEP290-associated renal disease has true translational promise and may provide a genetic rescue therapy for this severe ciliopathy syndrome.

In conclusion, we show that using ASO-mediated exon skipping rescues a ciliary defect in patient renal epithelial cells and can be used systemically to target CEP290 transcripts within kidney tissues, offering a therapeutic approach to treating inherited renal ciliopathies.

Materials and Methods

Study Approval. Ethical approval was obtained from the National Research Ethics Service Committee North East (14/NE/1076), United Kingdom. All animal experiments were conducted according to protocols approved by the Animal Ethics Committee of Newcastle University and the Home Office, United Kingdom.

Statistics. All data are shown as the mean ± SEM, unless otherwise stated and unpaired Student’s t test or one-way ANOVA followed by a Bonferroni corrected post hoc test when comparing two or more groups. A P value of less than 0.05 was considered statistically significant.

Clinical and DNA Sequencing. Following informed and written consent, urine and blood samples were obtained from a 14-yr-old boy with clinical JBTAs with a retinal, renal, and cerebellar phenotype and a healthy gender- and age-matched control. All methods were performed in accordance with the relevant ethical guidelines and regulations.

Sequencing of Joubert syndrome genes was performed by UKGTN using an 18 Gene Panel (Oxford Regional Genetic Laboratory Service). Confirmation of mutations and segregation analysis was performed on other family members, following informed consent, using Sanger sequencing, using exon specific primers.

In Vitro Studies Using Human Kidney and hURECs. Immunostaining of human kidney tissues from patients with CEP290 mutations was performed. In vitro studies following hUREC isolation (28), culture, and ASO treatments were performed, including Western immunostaining, Western blotting, and reverse transcription-PCR and quantitative RT-PCR. Electron microscopy studies were performed on hURECs. Please see SI Appendix for detailed materials and methods.

In Vivo ASO Treatment of Cep290 mutant Animals. In vivo studies were performed on 28-d-old Cep290 mutant animals. Renal tissues were harvested and used for immunofluorescence studies, Western blotting, RNA extraction, and reverse transcription-PCR and quantitative RT-PCR. Please see SI Appendix for detailed materials and methods.

ACKNOWLEDGMENTS. Thank you to the patient and family members who contributed to this study. This work is funded by The Medical Research Council (Award MRM101221211), a Kidney Research UK Post-doctoral fellowship (to S.A.R.) (Award PDF_003_20151124), and Northern Counties Kidney Research Fund. L.D. is funded by The Medical Research Council Discovery Medicine North Training Partnership.